PhaseBio makes three leadership changes
This article was originally published in Scrip
Executive Summary
Pennsylvania-based PhaseBio Pharmaceuticals, a company focused on finding biopolymer-based drugs to treat diabetes and cardiovascular dysfunctions, has made changes to its leadership team with a new chair, CEO and vice-president of research and scientific affairs.